Perspective Therapeutics establishes $50M ATM equity sales program

Perspective Therapeutics, Inc.

Entered into at-market issuance agreement with Oppenheimer, B. Riley, and JonesTrading on Nov 17, 2023.
May offer and sell up to $50,000,000 of common stock from time to time at the market.
Agents receive 3.0% commission on gross proceeds from sales effectuated through them.
Program is under a new S-3 registration statement (File No. 333-275638) filed with the SEC.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Perspective Therapeutics, Inc. entered into At Market Issuance Sales Agreement with Oppenheimer & Co. Inc., B. Riley Securities, Inc. and JonesTrading Institutional Services LLC valued at $50,000,000 (effective 2023-11-17).

Action: entry
Agreement: atm program
Counterparty: Oppenheimer & Co. Inc., B. Riley Securities, Inc. and JonesTrading Institutional Services LLC
Value: $50,000,000
Effective: 2023-11-17

Exact text from the filing

On November 17, 2023, Perspective Therapeutics, Inc. (the “Company”) entered into an At Market Issuance Sales Agreement (the “Agreement”) with Oppenheimer & Co. Inc., B. Riley Securities, Inc. and JonesTrading Institutional Services LLC (each, an “Agent” and together, the “Agents”) to create an “at-the-market” equity program under which the Company from time to time may offer and sell shares (the “ATM Shares”) of its common stock, par value $0.001 per share (“Company Common Stock”), through or to the Agents.

View on SEC.gov

230 material agreements filed in the last 30 days. Browse all material agreements →

Perspective Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001437749-23-032491

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.